Parkinson\'s Disease (PD) and sarcopenia are prevalent age-related syndromes, often occurring simultaneously within individuals. Sarcopenia is notably common among PD patients, with severe cases affecting approximately one in every five individuals with PD. Moreover, sarcopenia is closely linked to the accelerated progression of PD, diminished quality of life, heightened mortality risk, and increased susceptibility to falls and fractures. Therefore, early detection of sarcopenia assumes particular significance as it offers an opportunity for interventions aimed at mitigating or delaying muscle degeneration, potentially influencing PD outcomes. This review will delve into the relationship between sarcopenia and PD, methods for screening and testing sarcopenia, and potential avenues for further research and the development of strategies for risk reduction and treatment
None
None
Age ≥ 30 years
Cohort
Retrospective
Not listed
the SARC-F
The SARC-F is a simple screening tool for sarcopenia, consisting of five questions on strength, assistance in walking, rising from a chair, climbing stairs, and falls. Each question is scored from 0 to 2, with a total score of 4 or more indicating a risk of sarcopenia.
Low Muscle Mass
The Skeletal Muscle Mass Index (SMI) is a measure used to assess muscle mass relative to a person's height. It is calculated by dividing the total skeletal muscle mass (usually obtained through techniques like DXA or BIA) by the square of the individual's height (in meters)
Low Muscle Strength
Commonly assessed using grip strength tests
Poor Physical Performance
Evaluated through tests like gait speed, the Short Physical Performance Battery (SPPB), or the Timed Up and Go (TUG) test.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
